Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

High Efficacy of Liposomal Annamycin (L-ANN) in Combination with Cytarabine in Syngeneic p53-Null AML Mouse Model

Tomasz Zal, PhDMSc, Rafal Zielinski, PhD, Krzysztof Grela, MSc, Roberto Cardenas-Zuniga, Stanislaw Skora, PhD, Izabela Fokt, PhD, Malgorzata Anna Zal, MSc, Michael Andreeff, MD PhD, Lidia Gil, MDPhD, Robert Shephard, MD PhD, Waldemar Priebe, PhD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-143344

Published: 2020

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Stage I, II or III Mycosis Fungoides (MF)

Malgorzata Sokołowska-Wojdyło, MD, Izabela Blazewicz, PhD, Berenika Olszweska, PhD, Ewa Maria Zak, MSc, Walter Klemp, Sandra L Silberman, MD PhD, Waldemar Priebe, PhD

Blood (2019) 134 (Supplement_1): 5272.

https://doi.org/10.1182/blood-2019-125118

Published: 2019

Journal Articles

Clinical Efficacy of L-Annamycin, a Liposomal Formulated Non-Cross-Resistant and Non-Cardiotoxic Anthracycline in Relapsed/Refractory AML Patients

Lidia Gil, MD PhD, Robert C. Shepard, MD, Sandra L Silberman, MD PhD, Ewa Maria Zak, MSc, Waldemar Priebe, PhD

Blood (2019) 134 (Supplement_1): 5147.

https://doi.org/10.1182/blood-2019-129268

Published: 2019

Journal Articles

Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model

Rafal Zielinski, PhD, Krzysztof Grela, PhD, Stanislaw Skora, PhD, Rodrigo Jacamo, PhD, Izabela Fokt, PhD, Matthew Sander, Magdalena Remiszewski, PhD, Edward Felix, PhD, Meenakshi Shanmugasundaram, Malgorzata Anna Zal, MSc, Michael Andreeff, MD PhD, Waldemar Priebe, PhD, Tomasz Zal, PhD

Blood (2019) 134 (Supplement_1): 5150.

https://doi.org/10.1182/blood-2019-131977

Published: 2019

Journal Articles

Potent Inhibition of the Growth and Induction of Apoptosis of Mantle Cell Lymphoma By the Novel Anthracycline Berubicin in Vitro and in Vivo

George Tsourdinis, Hyebin Park, Luhong Sun, MD PhD, Izabela Fokt, PhD, Arumugam Jayakumar, MSc, PhD, Hui Zhang, Qingqing Cai, MD PhD, Dehui Zou, Bingliang Fang, MD PhD, Waldemar Priebe, PhD, Michael Wang, MD, Liang Zhang, MD PhD

Blood (2014) 124 (21): 3106.

https://doi.org/10.1182/blood.V124.21.3106.3106

Published: 2014

Journal Articles

Atiprimod Inhibits the JAK-STAT Pathway and Induces Apoptosis in Human Cells Carrying the JAK2 V617F or JAK3 Mutation.

Taghi Manshouri, PhD, Mirna Golemovic, PhD, Hagop M.M. Kantarjian, MD, Jorge E. Cortes, MD, Ying Zhang, MD, Waldemar Priebe, PhD, Zeev Estrov, MD, Srdan Verstovsek, MD.PhD

Blood (2007) 110 (11): 3556.

https://doi.org/10.1182/blood.V110.11.3556.3556

Published: 2007

Journal Articles

Atiprimod Inhibits the Growth of JAK2 Tyrosine Kinase Over-Expressing Cells “In Vitro” and “Ex Vivo”.

Roberto Nussenzveig, PhD, Taghi Manshouri, PhD, Hagop Kantarjian, MD, Francis Giles, MD, Jorge Cortes, MD, Amos Gaikwad, PhD, Waldemar Priebe, PhD, Zeev Estrov, MD, Srdan Verstovsek, MD

Blood (2006) 108 (11): 4924.

https://doi.org/10.1182/blood.V108.11.4924.4924

Published: 2006

Journal Articles

WP1066 Inhibits Growth of Human Cells Carrying the JAK2 V617F Mutation.

Taghi Manshouri, PhD, Zeev Estrov, M.D., Alfonso Quintas-Cardama, M.D., Jorge Cortes, M.D., Francis Giles, M.D., David Harris, MS, Waldemar Priebe, PhD;MS, Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD.

Blood (2006) 108 (11): 4885.

https://doi.org/10.1182/blood.V108.11.4885.4885

Published: 2006

Journal Articles

Activation of a Novel Proteasomal Independent Bcr/Abl Degradation Pathway by WP1130 Induces Apoptosis in CML Cells.

Geoffrey A. Bartholomeusz, PhD, Nichalos Donato, PhD, Zeev Estrov, MD, Waldemar Priebe, PhD, Moshe Talpaz, MD

Blood (2005) 106 (11): 2862.

https://doi.org/10.1182/blood.V106.11.2862.2862

Published: 2005

Journal Articles

WP1066: A Novel PI-3K Inhibitor with Antileukemic Activity in Philadelphia Chromosome-Positive ALL.

Alessandra Ferrajoli, MD, Stefan Faderl, MD, Tony Wang, Waldemar Priebe, PhD, Hagop Kantarjian, MD, Moshe Talpaz, MD, Zeev Estrov, MD

Blood (2005) 106 (11): 850.

https://doi.org/10.1182/blood.V106.11.850.850

Published: 2005

Journal Articles

Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Ling-Yuan Kong, MD, PhD, Vaibhav Kapuria, Geoffrey Bartholomeusz, PhD, Moshe Talpaz, MD, Waldemar Priebe, PhD, Nicholas J. Donato, PhD

Blood (2005) 106 (11): 1489.

https://doi.org/10.1182/blood.V106.11.1489.1489

Published: 2005

Journal Articles

WP-1034, a Novel Jak-Stat Inhibitor, Has Proapoptotic and Antileukemic Activity in Acute Myeloid Leukemia (AML) Cell Lines and AML Patient Samples.

Stefan Faderl, MD, Alessandra Ferrajoli, MD, David Harris, Quin Van, Waldemar Priebe, PhD, Zeev Estrov, MD

Blood (2004) 104 (11): 2528.

https://doi.org/10.1182/blood.V104.11.2528.2528

Published: 2004

Journal Articles

Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia.

Nicholas J. Donato, PhD, Ji Wu, MD, Ling Y. Kong, MD, PhD, Feng Meng, MD, Waldemar Priebe, PhD, Moshe Talpaz, MD

Blood (2004) 104 (11): 2964.

https://doi.org/10.1182/blood.V104.11.2964.2964

Published: 2004

NARROW

High Efficacy of Liposomal Annamycin (L-ANN) in Combination with Cytarabine in Syngeneic p53-Null AML Mouse Model

A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Stage I, II or III Mycosis Fungoides (MF)

Clinical Efficacy of L-Annamycin, a Liposomal Formulated Non-Cross-Resistant and Non-Cardiotoxic Anthracycline in Relapsed/Refractory AML Patients

Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model

Potent Inhibition of the Growth and Induction of Apoptosis of Mantle Cell Lymphoma By the Novel Anthracycline Berubicin in Vitro and in Vivo

Atiprimod Inhibits the JAK-STAT Pathway and Induces Apoptosis in Human Cells Carrying the JAK2 V617F or JAK3 Mutation.

Atiprimod Inhibits the Growth of JAK2 Tyrosine Kinase Over-Expressing Cells “In Vitro” and “Ex Vivo”.

WP1066 Inhibits Growth of Human Cells Carrying the JAK2 V617F Mutation.

Activation of a Novel Proteasomal Independent Bcr/Abl Degradation Pathway by WP1130 Induces Apoptosis in CML Cells.

WP1066: A Novel PI-3K Inhibitor with Antileukemic Activity in Philadelphia Chromosome-Positive ALL.

Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma.

WP-1034, a Novel Jak-Stat Inhibitor, Has Proapoptotic and Antileukemic Activity in Acute Myeloid Leukemia (AML) Cell Lines and AML Patient Samples.

Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only